Abstract Purpose: The effects of stress-dose corticosteroid therapy were studied in a canine staphylococcal pneumonia model of septic shock. Methods: Immediately following intrabronchial bacterial challenge, purpose-bred beagles were treated with stress doses of desoxycorticosterone (DOC), a mineralocorticoid agonist, and dexamethasone (DEX), a glucocorticoid agonist, or with placebo for 96 h. Oxacillin (30 mg/kg every 8 h) was started 4 h after infection onset. Bacterial dose was titrated to achieve 80-90 % lethality (n = 20) using an adaptive design; additional animals (n = 18) were investigated using the highest bacterial dose. Results: Initial analysis of all animals (n = 38) demonstrated that the effects of DOC ? DEX were significantly altered by bacterial dose (p = 0.04). The treatment effects of DOC ? DEX were different in animals administered high or relatively lower bacterial doses in terms of survival (p = 0.05), shock reversal (p = 0.02), interleukin-6 levels (p = 0.02), and temperature (p = 0.01). DOC ? DEX significantly improved the above parameters (p B 0.03 for all) and lung injury scores (p = 0.02) after high-dose bacterial challenges, but not after lower challenges (p = not significant for all). Oxacillin trough levels were below the minimum inhibitory concentration of the infecting organism, and DOC ? DEX increased the frequency of persistent staphylococcal bacteremia (odds ratio 3.09; 95 % confidence interval 1.05-9.11; p = 0.04). Conclusions: Stressdose corticosteroids were only beneficial in cases of sepsis with high risk for death and even short courses may interfere with host mechanisms of bacterial clearance.
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Introduction
During the last decade, the concept that relative adrenal insufficiency contributes to the poor outcome of septic shock prompted clinical trials of physiologic stress-dose corticosteroid therapy [i.e., 200-300 mg of hydrocortisone (or equivalent) per day given for 5-11 days] . The effect of corticosteroids on survival varied across these trials [1, 2] . Meta-regression analysis results suggested that stress-dose corticosteroids might confer a survival benefit only in septic shock patients at high risk of death [3, 4] . Notably, sepsis-associated risk of death has been shown to similarly influence the efficacy of mediatorspecific anti-inflammatory therapies [5] . In the case of physiologic stress-dose corticosteroids however, the finding that treatment efficacy was dependent on severity of illness was based on 12 relatively small trials [median 44 patients, interquartile range (IQR) 41-44] potentially confounded by publication bias [3] . Therefore, despite an apparent ameliorative effect of stress-dose corticosteroids on vasopressor-dependent shock during sepsis, the lack of a reproducible survival benefit has made the use of these medications in sepsis controversial.
Glucocorticoid-associated increases in secondary infections or impairment of bacterial clearance may underlie the variable results on survival observed with corticosteroid therapy. Corticosteroids over a wide range of glucocorticoid activity have been shown to impair host bacterial clearance from the lung [6] and blood [7] in animal models, although their precise effects in clinical sepsis are less clear [3, 8, 9] . Particularly in low-risk septic shock patients, an increased risk of infection with corticosteroid therapy may outweigh any benefits from reduced dependence on vasopressors. This could in part explain the variable mortality benefit reported in clinical sepsis trials [2, 3] .
In an attempt to gain a better understanding of the beneficial effects of corticosteroid therapy in septic shock, we previously investigated the effects of two different selective corticosteroid agonists in a canine model of Staphylococcus aureus pneumonia [10] . When administered alone, the glucocorticoid dexamethasone (DEX) given at the onset of infection reversed shock and produced a beneficial trend on survival. However, the mineralocorticoid desoxycorticosterone (DOC) was only beneficial when administered a few days before bacterial challenge. In the study reported here, we examined the effects of combination corticosteroid therapy (DOC ? DEX) in the same model. DOC ? DEX were given together at the onset of sepsis to simulate common clinical practice [11] (i.e., hydrocortisone has mixed mineralocorticoid and glucocorticoid agonist effects [12] ). In the initial phase of these experiments, the dose of bacterial challenge was titrated using a prospective adaptive design to create a highly lethal model (lethality rate of 80-90 %).
Methods
A full description of the methods is given in the Electronic Supplementary Material (ESM). Briefly, immediately following intrabronchial S. aureus challenge, mechanically ventilated and sedated purpose-bred beagles were treated with stress doses of DOC, a mineralocorticoid agonist, and DEX, a glucocorticoid agonist, or with placebo for 96 h. All animals received mechanical ventilation, sedation, intravenous fluids, and vasopressors titrated to physiologic endpoints throughout the study. Bacterial dose was titrated to achieve 80-90 % lethality (n = 20) using an adaptive design; additional animals (n = 18) were investigated using the highest bacterial dose. Oxacillin (30 mg/kg every 8 h) was started 4 h after infection onset. Data from the two studies were pooled to use all available data. A likelihood ratio test demonstrated an interaction between S. aureus challenge dose and treatment on survival, and bacterial doses were therefore divided into two groups (high-and low-bacterial dose groups, respectively) to minimize the within-group variation. Data were analyzed using exact log rank tests ( Fig. 1 ), F tests (baseline characteristics), and linear mixed models (Figs. 2-4 ). All p values are two-tailed and considered significant at p B 0.05.
Results

Survival
The effect of DOC ? DEX on survival was significantly altered by bacterial dose (p = 0.04, likelihood ratio test). Consequently, the animals were divided into a high-dose group (1.35-1.5 9 10 9 cfu/kg, n = 26) and a relatively lower dose group (low-dose group; 1.05-1.2 9 10 9 cfu/ kg, n = 12) to minimize the within-group dose variation. The administration of DOC ? DEX had significantly different effects on survival (Cox model, p = 0.05 for interaction) in the high-versus low-dose groups: DOC ? DEX given after high doses of bacterial challenge improved survival compared to controls (stratified logrank test p = 0.03; Fig. 1a ), but not after lower doses (stratified log-rank p = 0.69; (42 %) vs. 11/19 (58 %) respectively; p = ns] bacterial challenges. Likewise, there were no significant differences in bacterial colonization and/or possible superinfections, as determined by urine and catheter insertion site cultures in the DOC ? DEX-reated animals and controls at the high or lower doses of S. aureus alike throughout the study (p = ns for all; data not shown).
Oxacillin levels
Because the large percentage of positive blood cultures was unexpected, oxacillin levels were measured on stored samples from a subset of these experimental animals and supplemented with samples from similarly dosed septic animals in other studies (ESM). At 10 h after S. aureus challenge (i.e., 6 h after receiving the initial oxacillin dose; n = 48), the median oxacillin blood level was 0 (IQR 0-0) lg/mL regardless of S. aureus dosing or treatment with DOC ? DEX. At 24 h after S. aureus challenge (i.e., 4 h after the third oxacillin dose, n = 35), the median oxacillin blood level was 2.5 (IQR 0.0-7.1) lg/mL. At 48 h after S. aureus challenge (i.e., 4 h after the sixth oxacillin dose, n = 20), the median oxacillin blood level was 5.0 (IQR 2.5-30) lg/mL. The measured minimum inhibitory concentration for oxacillan was 0.5 lg/mL. These data indicate that despite dosing per standard veterinary practice [13] , oxacillin levels were likely to be inadequate at the end of each dosing interval, particularly early in the experiment. Marginal oxacillin dosing likely unmasked corticosteroid-associated impairment of bacterial clearance as manifested by persistently positive blood cultures.
Shock reversal and lung injury score At baseline (T0), prior to S. aureus challenge, there were no significant differences in mean shock reversal scores and lung injury scores between the two treatment groups and the controls (p = ns for all; Fig. 3 ). DOC ? DEX had different effects on shock reversal in the high-and low-dose S. aureus challenged groups (p = 0.02 for interaction): from 12 to 96 h following the administration of DOC ? DEX the mean shock reversal scores improved in the high-dose S. aureus challenged group compared to the controls (p = 0.009; Fig. 3a ), but shock reversal was not significantly altered in the low-dose challenged group (p = ns; Fig. 3b ). The administration of DOC ? DEX also improved mean lung injury scores from 12 to 96 h in the high-dose bacterial challenged group (p = 0.02; Fig. 3c ) but not in the low-dose one (p = ns; Fig. 3d) . However, the differences in the effect of DOC ? DEX on the lung injury score between the two groups did not 
Cytokines and temperature
At high versus lower doses of S. aureus challenge, DOC ? DEX had different effects on interleukin-6 (IL-6) levels and temperature (p = 0.02 and p = 0.01, respectively). Compared to the controls, DOC ? DEX suppressed the rise in IL-6 levels from 4 to 30 h after high-dose S. aureus challenge (p = 0.003; Fig. 4a ) and suppressed the rise in temperature from 12 to 96 h (p = 0.02; Fig. 4b ). However, DOC ? DEX did not significantly alter IL-6 levels or temperature in animals challenged with the relatively lower dose of S. aureus (p = ns for both; Fig. 4c, d ). In all 38 animals studied, IL-6 levels at 10 and 24 h after infection were negatively correlated with survival (r = -0.46 p = 0.004 and r = -0.83, p \ 0.0001, respectively). This correlation showed a similar strong negative correlation in the subgroup analysis regardless of bacterial dose or treatment group examined (ESM Fig. E2 ). There were no significant effects of DOC ? DEX at high or lower doses of bacteria on mean IL-10 levels compared to controls throughout the study (p = ns for all; data not shown).
Cardiac function, kidney and liver function, electrolytes, and hematology Compared to controls, from 12 to 30 h, DOC ? DEX decreased mean chloride level after the lower dose bacterial challenge (119.3 ± 2.1 vs. 124.7 ± 1.8 mmol/L; p = 0.01) and increased the mean creatinine level from 12 to 30 h after high-dose bacterial challenge (1.09 ± 0.35 vs. 0.80 ± 0.11 mg/dL; p = 0.02) (ESM Table  E1A ). Compared to the controls, there were no other significant differences following DOC ? DEX administration in the high-dose and low-dose challenged groups on cardiac function, kidney and liver function, electrolytes, or hematology (p = ns for all; ESM).
Discussion
Our results show that DEX, a selective glucocorticoid agonist, and DOC, a selective mineralocorticoid agonist, given together therapeutically in physiologic stress doses Fig. 4 Interleukin-6 (IL-6) levels and temperature. The treatment effects of DOC ? DEX on both IL-6 levels and temperature were different in the groups challenged with high and relatively lower bacterial doses, respectively. At high bacterial doses, DOC ? DEX suppressed the rise in IL-6 levels (a) and temperature (b) compared to controls. At relatively lower bacterial doses, DOC ? DEX had no significant effects on IL-6 levels (c) or temperature (d) improved the survival of canines subjected to high-dose S. aureus pulmonary challenge but not that in animals subjected to lower-dose S. aureus pulmonary challenge. The combined treatment also improved shock reversal and decreased lung injury, IL-6 levels, and fever in the highdose group, but not in the low-dose group. The relationship between risk and survival efficacy of a combined glucocorticoid and mineralocorticoid-based corticosteroid regimen is consistent with the results of clinical corticosteroid trials in sepsis [3] , as well as with findings regarding the efficacy of mediator-specific anti-inflammatory agents in sepsis [5] . Of concern is the finding that corticosteroid therapy increased bacteremia in a setting of marginal oxacillin trough levels, suggesting that even at stress-doses corticosteroids can interfere with host mechanisms of bacterial clearance. Highly effective antibiotic regimens are likely critical to ensure the safety of using shortterm corticosteroids in septic shock.
It has been postulated that the net effects of antiinflammatory agents in sepsis, including corticosteroids, represent a balance between their ability to beneficially limit potentially harmful host inflammation (e.g., cytokine production) versus the suppression of host defenses and microbial clearance [5, [14] [15] [16] [17] [18] . Notably, IL-6 levels increase with increased severity of illness [19] , and therapeutic DEX only appears to improve outcomes in animals with high but not lower IL-6 levels [20] . Given that IL-6 levels were significantly correlated with risk of death in this study, inhibition of an excessive inflammatory response in animals challenged with high doses of bacteria may have reduced temperature, shock, and end-organ injury and improved survival more than in animals receiving lower bacterial challenges. However, DOC ? DEX similarly hampered S. aureus clearance from the blood regardless of inoculation dose. Furthermore, we are unaware of a mechanism that might explain why corticosteroid therapy reduced IL-6 levels after highdose but not relatively lower dose bacterial challenges.
The ability of even short-term stress-dose corticosteroids to alter innate immune responses is perhaps underappreciated and even controversial. Studies on human monocytes [21, 22] and clinical trials [23] have provided some data suggesting that corticosteroids may actually improve phagocytosis and the killing of bacteria. However, the CORTICUS trial of stress-dose hydrocortisone therapy for patients with septic shock found a significant increase in superinfections in the treatment arm [2] . Stress-induced endogenous corticosteroids alone have also been shown to impair neutrophil function [24] and increase bacterial overgrowth in wounds [25] in rodent models. In addition, animal studies have repeatedly demonstrated that the administration of exogenous corticosteroids can impair host neutrophil-mediated bacterial clearance mechanisms [6, 7, 25] , which might explain the excess of positive blood cultures we observed in the DOC ? DEX-treated animals. More specific to our own study, corticosteroid therapy has been shown to decrease bacterial clearance from the lung in murine models [6] and is most efficacious when administered with appropriate antibiotic therapy [26] [27] [28] . These data suggest that appropriately selected antibiotic therapy is essential whenever corticosteroids are used in the treatment of septic shock. Of note, the infectious risks associated with corticosteroids and other immunosuppressive agents may be reduced with antibiotic coverage [29] [30] [31] . Thus, with better oxacillin dosing it is possible that corticosteroid therapy would have had greater beneficial effects in both the low-and high-bacterial dose groups in this study.
Our finding that DOC ? DEX improved shock reversal scores at high-dose but not lower-dose bacterial challenge may differ from the shock reversal effects of corticosteroid therapy that was found in clinical sepsis trials [3] . Overall, there was a significant improvement in shock reversal with stress-dose corticosteroids regardless of risk of death across these clinical studies. However, only seven of the 12 trials actually reported results on shock reversal [2, [32] [33] [34] [35] [36] [37] . Of these, only two studies demonstrated significant shock reversal effects, both of which reported high control mortality rates of 61 and 63 %, respectively [32, 35] . One low-risk trial (31 % control mortality) reported that treatment with stress-dose hydrocortisone improved shock reversal, but the effect was not statistically significant [2] . Moreover, corticosteroid treatment resulted in more episodes of new sepsis and septic shock secondary to an increased number of superinfections. It is possible that the DOC ? DEXtreated animals in the low-dose S. aureus group in our study did not experience a beneficial effect on shock reversal or survival as a result of immunosuppression (and subsequent worsening bacteremia) in the setting of minimal anti-inflammatory benefits.
Alternatively, there are likely additional variables that alter the risk-efficacy relationship of corticosteroid therapy in sepsis. In mice challenged with increasing intratracheal Escherichia coli doses, the benefit of hydrocortisone did not appear to vary across different severities of infection or mortality rates [38] . Notably, this model employed antibiotic coverage but not hemodynamic support. Furthermore, in a mouse model of sepsis, type of infecting organism, and timing of antibiotic coverage in relationship to corticosteroid therapy was found to alter treatment efficacy [30] . Whether these discrepancies are model based, therapy based, or a combination of the two requires further investigation.
Hydrocortisone, the corticosteroid most frequently administered in septic shock trials, has both glucocorticoid and mineralocorticoid agonist effects. In order to mimic the combined agonist properties of hydrocortisone, we investigated the use of a selective glucocorticoid (DEX) administered in combination with a selective mineralocorticoid (DOC). However, in a prior study investigating the effects of timing of corticosteroid administration in a highly lethal canine model of S. aureus pneumonia [10] , we found that DOC improved survival, shock reversal, and lung injury and lowered fluid requirements-but only if it was given before (i.e., prophylactically) and not at the time of (i.e., therapeutically) bacterial challenge. In contrast, while therapeutic DEX reversed shock and showed a trend toward prolonged survival, prophylactic DEX lowered aldosterone and cortisol levels, worsened shock acutely, and provided no overall survival benefit. Impairment of innate immunity by corticosteroids has been most closely associated with their glucocorticoid activity. However, our previous study directly comparing DEX and DOC at similar time points failed to detect significant differences in S. aureus blood culture positivity rates [10] . Nonetheless, the putative survival benefit and harmful effects on infection in both clinical trials of septic shock and our current investigation in canines seem to be most consistent with the glucocorticoid activity of stress-dose corticosteroid regimens. Clearly, the innate immune effects of corticosteroid regimens with different properties and varying degrees of glucocorticoid and mineralocorticoid activity require further investigation.
A comparison of the effects of therapeutic DEX alone on survival, shock, and lung injury score in our previous study of high-lethality septic shock [10] with the regimen of therapeutic DOC ? DEX given together in the present study reveals that the effects are remarkably similar (ESM Table  E1B ). Consistent with this notion, the addition of a selective mineralocorticoid to hydrocortisone therapy in a recent clinical sepsis trial failed to further improve outcome [39] . Hydrocortisone therapy itself has mineralocorticosteroid activity [12] . However, in our previous study, prophylactic DEX suppressed the hypothalamus-pituitary-adrenal (HPA) axis, resulting in lower aldosterone and cortisol levels [10] and suggesting that selective glucocorticoid therapy may eventually have adverse effects in prolonged episodes of septic shock. A better understanding of the specific influence of glucocorticoids on the HPA axis during sepsis may inform the design of future corticosteroid regimens. Since short courses of mineralocorticoids have minimal risks [40] , supplemental therapy with a mineralocorticoid agonist (or the use of hydrocortisone, which has intrinsic mineralocorticoid activity) would seem like a reasonable approach to the corticosteroid treatment of septic shock.
The present study has a number of limitations. A canine model, regardless of methodology that simulates key aspects of the pathogenesis and management of sepsis clinically, cannot mimic the complexity of a heterogeneous patient population with different types and severity of infections. Also, we only examined survival over 96 h and our sample sizes were small, so it is unknown if the observed survival benefits would translate into improved long-term survival. Moreover, because the sample size of our experiment was relatively small, a change in the mortality of a few animals could have affected the results. In addition, two studies were combined in a post hoc analysis. After we found that the effect of corticosteroids on survival was significantly altered by bacterial dose, we divided the animals into two groups (low-and high-dose groups) for analysis. Thus, future prospective studies are necessary to confirm the findings suggested by our study. We have also studied only one corticosteroid regimen, and its activity may not be similar to the effects of hydrocortisone [12] or other corticosteroid regimens and doses. Finally, the oxacillin dose and/or dosing interval used in this study produced marginal trough levels. While this unintentional occurrence likely unmasked the deleterious effect of DOC ? DEX on bacterial clearance, more adequate oxacillin dosing would be expected to eliminate this potential harmful effect on corticosteroids and alter mortality rates.
In conclusion, a corticosteroid regimen with both glucocorticoid and mineralocorticoid activity had beneficial effects on shock reversal, lung injury, inflammatory mediators, and survival in high-risk septic animals only. The findings presented here and in our previous study [10] suggest a need for new randomized clinical trials to further evaluate the potential efficacy of mixed corticosteroid regimens in sepsis. These studies may require new methods to aid the selection of relatively homogeneous, highly specific patient populations, such as high-risk patients with severe septic shock [3] . In addition, our data suggest that if stress-dose exogenous corticosteroids are used in septic patients, adequately dosed and appropriately selected antibiotic therapy is critical to mitigate potential interference with host mechanisms of bacterial clearance.
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